NO20062780L - Eksipienter i legemiddelleveringsvehikler - Google Patents

Eksipienter i legemiddelleveringsvehikler

Info

Publication number
NO20062780L
NO20062780L NO20062780A NO20062780A NO20062780L NO 20062780 L NO20062780 L NO 20062780L NO 20062780 A NO20062780 A NO 20062780A NO 20062780 A NO20062780 A NO 20062780A NO 20062780 L NO20062780 L NO 20062780L
Authority
NO
Norway
Prior art keywords
polymers
excipients
drug delivery
delivery vehicles
soften
Prior art date
Application number
NO20062780A
Other languages
English (en)
Norwegian (no)
Inventor
Guohua Chen
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Publication of NO20062780L publication Critical patent/NO20062780L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20062780A 2003-11-14 2006-06-14 Eksipienter i legemiddelleveringsvehikler NO20062780L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US51993603P 2003-11-14 2003-11-14
US10/985,122 US20050106214A1 (en) 2003-11-14 2004-11-10 Excipients in drug delivery vehicles
PCT/US2004/037781 WO2005049069A1 (en) 2003-11-14 2004-11-12 Excipients in drug delivery vehicles

Publications (1)

Publication Number Publication Date
NO20062780L true NO20062780L (no) 2006-08-14

Family

ID=34576891

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20062780A NO20062780L (no) 2003-11-14 2006-06-14 Eksipienter i legemiddelleveringsvehikler

Country Status (12)

Country Link
US (2) US20050106214A1 (pt)
EP (1) EP1691826A4 (pt)
JP (1) JP4916887B2 (pt)
KR (1) KR20060125749A (pt)
AU (2) AU2004291093A1 (pt)
BR (1) BRPI0416590A (pt)
CA (1) CA2545923A1 (pt)
IL (1) IL175602A0 (pt)
MX (1) MXPA06005463A (pt)
NO (1) NO20062780L (pt)
TW (1) TW200529842A (pt)
WO (1) WO2005049069A1 (pt)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1446101B1 (en) * 2001-11-14 2011-03-23 Durect Corporation Catheter injectable depot compositions and uses thereof
RU2355385C2 (ru) * 2002-11-06 2009-05-20 Алза Корпорейшн Композиции пролонгированного действия с контролируемым высвобождением
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
US20050281879A1 (en) * 2003-11-14 2005-12-22 Guohua Chen Excipients in drug delivery vehicles
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US20060252831A1 (en) * 2005-05-06 2006-11-09 Christopher Offen Method for the treatment of magnesium and potassium deficiencies
US20060252830A1 (en) * 2005-05-06 2006-11-09 Brandon Stephen F Method for the treatment of magnesium and potassium deficiencies
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
EP1912627B1 (en) * 2005-08-11 2016-08-10 Promedon S.A. Composition comprising polymeric, water-insoluble, anionic particles, processes and uses
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
US7261742B2 (en) * 2005-10-13 2007-08-28 S.C. Johnson & Son, Inc. Method of deodorizing a textile
US7407922B2 (en) * 2005-10-13 2008-08-05 S.C. Johnson & Son, Inc. Deodorizing compositions
KR101106510B1 (ko) 2006-05-30 2012-01-20 인타르시아 세라퓨틱스 인코포레이티드 투피스, 내부채널 삼투압 전달 시스템 유동 조절기
EP1872807A1 (en) * 2006-06-30 2008-01-02 Scil Technology GmbH Biomaterial containing degradation stabilized polymer
EP2359808B1 (en) 2006-08-09 2013-05-22 Intarcia Therapeutics, Inc Osmotic delivery systems and piston assemblies
US20080187604A1 (en) 2006-10-05 2008-08-07 Ikaria, Inc. Liquid chalcogenide compositions and methods of manufacturing and using the same
CA2667890C (en) * 2006-10-31 2015-01-27 Surmodics Pharmaceuticals, Inc. Spheronized polymer particles
WO2008133908A2 (en) 2007-04-23 2008-11-06 Intarcia Therapeutics, Inc. Suspension formulations of insulinotropic peptides and uses thereof
ES2562878T3 (es) 2007-05-25 2016-03-08 Indivior Uk Limited Formulaciones de liberación sostenida de compuestos de risperidona
CA2726861C (en) 2008-02-13 2014-05-27 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
RU2547990C2 (ru) 2009-09-28 2015-04-10 Интарсия Терапьютикс, Инк. Быстрое достижение и/или прекращение существенной стабильной доставки лекарственного средства
CN102233129B (zh) * 2010-04-29 2014-07-09 上海交通大学 一种预防或治疗视网膜损伤的长效缓释制剂及其制备方法
WO2012003210A1 (en) * 2010-06-30 2012-01-05 Surmodics Pharmaceuticals, Inc. Implant processing methods for thermally labile and other bioactive agents and implants prepared from same
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
KR101494594B1 (ko) 2011-08-30 2015-02-23 주식회사 종근당 약리학적 활성물질의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
AU2013366692B2 (en) 2012-12-21 2017-11-23 Sanofi Dual GLP1/GIP or trigonal GLP1/GIP/Glucagon agonists
KR101586790B1 (ko) 2012-12-28 2016-01-19 주식회사 종근당 음이온성 약리학적 활성물질의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물
EA033537B1 (ru) 2013-03-11 2019-10-31 Durect Corp Инъекционная композиция с контролируемым высвобождением, содержащая жидкий носитель с высокой вязкостью
US20140308352A1 (en) 2013-03-11 2014-10-16 Zogenix Inc. Compositions and methods involving polymer, solvent, and high viscosity liquid carrier material
EP3080154B1 (en) 2013-12-13 2018-02-07 Sanofi Dual glp-1/gip receptor agonists
WO2015086733A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/glucagon receptor agonists
EP3080152A1 (en) 2013-12-13 2016-10-19 Sanofi Non-acylated exendin-4 peptide analogues
WO2015086728A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
KR102304113B1 (ko) 2014-02-10 2021-09-24 프레드 헛친슨 켄서 리서치 센터 심장마비 및 허혈성 손상의 할로겐 치료
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
KR101686986B1 (ko) 2014-07-28 2016-12-16 에스케이케미칼주식회사 류프로라이드를 포함하는 속효성과 지속성을 동시에 갖는 약제학적 조성물
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
CA3015557C (en) 2014-11-07 2019-07-16 Indivior Uk Limited The use of sustained-release buprenorphine formulations for the treatment of pain or opioid use disorders
RU2730996C2 (ru) 2015-06-03 2020-08-26 Интарсия Терапьютикс, Инк. Системы установки и извлечения имплантата
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
TW201706291A (zh) 2015-07-10 2017-02-16 賽諾菲公司 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
KR20180088415A (ko) * 2015-11-23 2018-08-03 그레이스 테라퓨틱스 엘엘씨 국소적 막형성 스프레이
WO2017193066A1 (en) * 2016-05-05 2017-11-09 Liquidia Technologies, Inc. Precision controlled load and release particles for post-operative pain
KR102574993B1 (ko) 2016-05-16 2023-09-06 인타르시아 세라퓨틱스 인코포레이티드 글루카곤-수용체 선택적 폴리펩티드 및 이들의 이용 방법
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
CN109477044B (zh) 2016-07-19 2021-10-08 艺康美国股份有限公司 用于去除口香糖和其它粘性食物的方法和清洁溶液
JP7286542B2 (ja) 2017-01-03 2023-06-05 インターシア セラピューティクス，インコーポレイティド Ｇｌｐ－１受容体アゴニストの持続的投与及び薬物の同時投与を含む方法
US10646484B2 (en) 2017-06-16 2020-05-12 Indivior Uk Limited Methods to treat opioid use disorder
CN115666621A (zh) 2020-01-13 2023-01-31 度勒科特公司 具有减少的杂质的持续释放药物递送系统及相关方法
CN111388744B (zh) * 2020-01-15 2021-05-18 华中科技大学 一种凝胶贮库及其制法与制备术后止血制剂的应用
CA3203561A1 (en) 2021-01-12 2022-07-21 Adrian Neil Verity Sustained release drug delivery systems and related methods
CN118201599A (zh) * 2021-12-24 2024-06-14 四川科伦药物研究院有限公司 一种可平稳释放的持续性递送制剂及其制备方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4443340A (en) * 1981-10-09 1984-04-17 Betz Laboratories, Inc. Control of iron induced fouling in water systems
US4985404A (en) * 1984-10-04 1991-01-15 Monsanto Company Prolonged release of biologically active polypeptides
US4853218A (en) * 1987-02-24 1989-08-01 Schering Corporation Zinc-protamine-alpha interferon complex
ES2139646T3 (es) * 1991-12-19 2000-02-16 Mitsui Chemicals Inc Acido polihidroxido carboxilico y su procedimiento de obtencion.
US5192743A (en) * 1992-01-16 1993-03-09 Genentech, Inc. Reconstitutable lyophilized protein formulation
DE69311538D1 (de) * 1992-03-12 1997-07-17 Alkermes Inc Acth enthaltende mikrokugeln mit gesteuerter abgabe
US5656297A (en) * 1992-03-12 1997-08-12 Alkermes Controlled Therapeutics, Incorporated Modulated release from biocompatible polymers
US5711968A (en) * 1994-07-25 1998-01-27 Alkermes Controlled Therapeutics, Inc. Composition and method for the controlled release of metal cation-stabilized interferon
US5242910A (en) * 1992-10-13 1993-09-07 The Procter & Gamble Company Sustained release compositions for treating periodontal disease
CA2150803C (en) * 1992-12-02 2006-01-31 Henry Auer Controlled release growth hormone containing microspheres
US5626862A (en) * 1994-08-02 1997-05-06 Massachusetts Institute Of Technology Controlled local delivery of chemotherapeutic agents for treating solid tumors
JP4642946B2 (ja) * 1996-12-20 2011-03-02 アルザ コーポレイション ゲル組成物および方法
RU2184564C2 (ru) * 2000-01-28 2002-07-10 Общество С Ограниченной Ответственностью "Ферон" Лекарственный гель
US20030211974A1 (en) * 2000-03-21 2003-11-13 Brodbeck Kevin J. Gel composition and methods
US6495534B2 (en) * 2000-05-15 2002-12-17 Pharmacia & Upjohn Spa Stabilized aqueous suspensions for parenteral use
US20020150621A1 (en) * 2000-10-16 2002-10-17 Kohane Daniel S. Lipid-protein-sugar particles for drug delivery
ATE427760T1 (de) * 2001-02-23 2009-04-15 Genentech Inc Erodierbare polymere zur injektion
CA2446060A1 (en) * 2001-05-07 2002-11-14 Corium International Compositions and delivery systems for administration of a local anesthetic agent
EP1446101B1 (en) * 2001-11-14 2011-03-23 Durect Corporation Catheter injectable depot compositions and uses thereof
DE60239952D1 (de) * 2001-11-14 2011-06-16 Durect Corp Injizierbare depotzusammensetzungen und deren verwendung
WO2003092585A2 (en) * 2002-05-02 2003-11-13 Pr Pharmaceuticals, Inc. Controlled release compositions of estradiol metabolites
AR039729A1 (es) * 2002-06-25 2005-03-09 Alza Corp Formulaciones de deposito de corta duracion
RU2355385C2 (ru) * 2002-11-06 2009-05-20 Алза Корпорейшн Композиции пролонгированного действия с контролируемым высвобождением
US20050281879A1 (en) * 2003-11-14 2005-12-22 Guohua Chen Excipients in drug delivery vehicles

Also Published As

Publication number Publication date
US20120177697A1 (en) 2012-07-12
TW200529842A (en) 2005-09-16
AU2011201826A1 (en) 2011-05-19
EP1691826A4 (en) 2012-08-22
IL175602A0 (en) 2006-09-05
CA2545923A1 (en) 2005-06-02
BRPI0416590A (pt) 2007-01-30
JP4916887B2 (ja) 2012-04-18
US20050106214A1 (en) 2005-05-19
MXPA06005463A (es) 2006-08-11
JP2007511524A (ja) 2007-05-10
KR20060125749A (ko) 2006-12-06
WO2005049069A1 (en) 2005-06-02
AU2011201826B2 (en) 2013-06-13
AU2004291093A1 (en) 2005-06-02
EP1691826A1 (en) 2006-08-23

Similar Documents

Publication Publication Date Title
NO20062780L (no) Eksipienter i legemiddelleveringsvehikler
NO20062781L (no) Eksipienter i legemiddelleveringsvehikler
DK1061900T3 (da) Dermale præparater
AR044926A1 (es) Sistema de suministro de farmacos gelificante in situ
PL335571A1 (en) Stabilisation of acid-sensitive benzimidazoles by combining them with amino acids and cyclodextrins
NO20040917L (no) Oftamologiske depotpreparater for periokular eller subkonjunktival administrering.
CY1116747T1 (el) Θεραπεια συνδυασμου για τη θεραπευτικη αγωγη διαταραχων ανεπαρκειας πρωτεϊνης
CA2430995A1 (en) Reversible gelling system for ocular drug delivery
IL154888A (en) Aqueous Pharmaceutical Gel Preparation Containing At least One Vitamin D or One Vitamin D Analog At least One Corticosteroid
DE69721481D1 (de) Wirkstoffformulierungen mit verzögerter freisetzung
TW200605915A (en) Drug delivery compositions
CY1105120T1 (el) Η αντιμετωπιση αναπνευστικων νοσων
MXPA02011304A (es) Derivados de piperidina farmaceuticamente activos, en partiular como moduladores de la actividad del receptor de la quimocina.
NO20015584D0 (no) Lantidsvarende insulintrofiske peptider
MXPA02012164A (es) Derivados de tiofeno activos como inhibidores de cinasa, proceso para su preparacion y composiciones farmaceuticas que los comprenden.
GB0102687D0 (en) Oxazolyl-pyrazole derivatives active as kinase inhibitors,process for their preparation and pharmaceutical compositions comprising them
DK1296647T3 (da) Polymermicellepræparater
BRPI0506983A (pt) composições para terapia localizada dos olhos, compreendendo preferencialmente acetonida de triancinolona e ácido hialurÈnico
UY25544A1 (es) Forma de dosificación de nefazodona
UY27929A1 (es) Composiciones farmaceuticas de farmacos semiordenados y polimeros
DK1280558T3 (da) Halvfast indgivelsesvehikel og farmaceutiske sammensætninger
WO2020087057A8 (en) Macromolecular prodrug-based thermosensitive injectable gel as a novel drug delivery platform
BRPI0406858A (pt) Liberação controlada de agentes altamente solúveis
NO20030073L (no) Medikamentleveringssystem for medikamenter som er lite vannopplöselige
PA8615501A1 (es) Formulaciones farmaceuticas transdermicas

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application